Columbia Asset Management lessened its position in Inogen, Inc (NASDAQ:INGN) by 9.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,570 shares of the medical technology company’s stock after selling 1,950 shares during the quarter. Columbia Asset Management owned 0.09% of Inogen worth $1,771,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. bought a new position in Inogen in the first quarter valued at $109,000. Schroder Investment Management Group bought a new position in Inogen in the second quarter valued at $132,000. Victory Capital Management Inc. increased its stake in Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after acquiring an additional 459 shares during the last quarter. State of Alaska Department of Revenue increased its stake in Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock valued at $138,000 after acquiring an additional 70 shares during the last quarter. Finally, Sei Investments Co. increased its stake in Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after acquiring an additional 443 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “Inogen, Inc (INGN) Shares Sold by Columbia Asset Management” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/09/10/inogen-inc-ingn-shares-sold-by-columbia-asset-management.html.
INGN has been the topic of a number of research analyst reports. BidaskClub cut Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Needham & Company LLC reissued a “buy” rating and issued a $108.00 target price on shares of Inogen in a research note on Friday, September 1st. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, J P Morgan Chase & Co increased their target price on Inogen to $102.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $91.60.
Shares of Inogen, Inc (NASDAQ:INGN) traded up 2.24% on Friday, hitting $103.05. The stock had a trading volume of 246,209 shares. The company has a 50 day moving average price of $94.82 and a 200-day moving average price of $86.16. The stock has a market cap of $2.14 billion, a PE ratio of 89.45 and a beta of 1.02. Inogen, Inc has a 12 month low of $50.24 and a 12 month high of $104.06.
Inogen (NASDAQ:INGN) last posted its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. During the same period in the previous year, the firm posted $0.25 EPS. The business’s quarterly revenue was up 17.4% on a year-over-year basis. On average, equities research analysts anticipate that Inogen, Inc will post $1.21 earnings per share for the current year.
In other news, Director Raymond Huggenberger sold 15,300 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $90.88, for a total value of $1,390,464.00. Following the sale, the director now directly owns 7,808 shares in the company, valued at approximately $709,591.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Heath Lukatch sold 2,500 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $97.44, for a total transaction of $243,600.00. Following the completion of the sale, the director now owns 2,500 shares in the company, valued at $243,600. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,967 shares of company stock worth $5,532,015. Insiders own 5.31% of the company’s stock.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc (NASDAQ:INGN).
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.